| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,330,000 |
| Market
Cap: |
11.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2235 - $0.2235 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. Co.'s product candidate, FMX114, which is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis. Co. is also in the preclinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Co.'s initial BET inhibitor candidate in development is VYN201, an administered pan-BET inhibitor, which it is exploring in various immuno-inflammatory diseases, including skin diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
13,000 |
43,000 |
| Total Buy Value |
$0 |
$0 |
$50,778 |
$125,458 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
1 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-11-30 |
4 |
A |
$1.45 |
$11,326 |
D/D |
7,838 |
358,722 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-09-30 |
4 |
D |
$1.66 |
$10,357 |
D/D |
(6,239) |
1,309,727 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-09-30 |
4 |
D |
$1.66 |
$3,025 |
D/D |
(1,822) |
317,065 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2020-09-30 |
4 |
D |
$1.66 |
$3,947 |
D/D |
(2,378) |
288,640 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-09-30 |
4 |
D |
$1.66 |
$2,558 |
D/D |
(1,541) |
350,884 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-09-08 |
4 |
B |
$1.38 |
$103,568 |
D/D |
75,000 |
1,315,966 |
2.81 |
35% |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2020-09-08 |
4 |
B |
$1.46 |
$58,480 |
D/D |
40,000 |
340,000 |
2.74 |
35% |
|
| Barbari Sharon Surrey |
Director |
– • – |
2020-08-20 |
4 |
OE |
$1.48 |
$111,000 |
D/D |
75,000 |
75,000 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-06-30 |
4 |
D |
$1.73 |
$10,793 |
D/D |
(6,239) |
1,240,966 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2020-06-30 |
4 |
D |
$1.73 |
$4,114 |
D/D |
(2,378) |
291,018 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-06-30 |
4 |
D |
$1.73 |
$2,666 |
D/D |
(1,541) |
352,425 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-06-30 |
4 |
D |
$1.73 |
$3,152 |
D/D |
(1,822) |
318,887 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2020-06-09 |
4 |
B |
$1.85 |
$4,999,999 |
I/I |
2,702,702 |
22,876,410 |
2.25 |
-7% |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
320,712 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
353,967 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
300,000 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
680,000 |
1,247,213 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
112,500 |
293,401 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2020-04-06 |
4 |
D |
$1.40 |
$5,268 |
D/D |
(3,763) |
180,901 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-04-06 |
4 |
D |
$1.40 |
$1,271 |
D/D |
(908) |
203,967 |
|
- |
|
| Harsch Mutya |
Chief Legal Officer and GC |
• – – |
2020-04-06 |
4 |
D |
$1.40 |
$6,264 |
D/D |
(4,474) |
170,712 |
|
- |
|
| Domzalski David |
President and CEO |
• • – |
2020-04-06 |
4 |
D |
$1.40 |
$16,481 |
D/D |
(11,772) |
567,213 |
|
- |
|
| Stuart Iain |
Chief Scientific Officer |
• – – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
125,212 |
184,664 |
|
- |
|
| Bruno Anthony D |
Director |
– • – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
90,623 |
135,056 |
|
- |
|
| Wiley Matthew T. |
Chief Commercial Officer |
• – – |
2020-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
137,824 |
204,875 |
|
- |
|
165 Records found
|
|
Page 5 of 7 |
|
|
